Metabolic dysfunction-associated steatotic liver disease
ICD-10 K76.0 · ICD-11 DB92

Treatment of MASLD / NASH in Patients with Type 2 Diabetes Mellitus

Nonalcoholic steatohepatitis (NASH) — the active, inflammatory form of metabolic dysfunction-associated steatotic liver disease — poses a distinct management challenge when it occurs alongside concurrent type 2 diabetes mellitus (T2DM). This page outlines the first-line structured approach for this specific patient population.

Clinical Scenario

Nonalcoholic steatohepatitis with concurrent type 2 diabetes mellitus. The co-occurrence of T2DM in this setting is clinically significant and shapes both the treatment priorities and the monitoring targets in this first-line protocol.

First-Line Approach — partial overview

The primary intervention is a structured liver-protective lifestyle programme. This includes a specific dietary strategy targeting a caloric deficit — with a particular dietary pattern recommended — alongside a defined physical activity regimen. The full protocol also addresses additional lifestyle factors relevant to the degree of hepatic fibrosis present.

Complete regimen details, sequencing, and individualised targets are available in the full structured protocol below.

Clinical Goals

Weight loss of 3%–5% improves hepatic steatosis, while weight loss greater than 10% is generally required to improve NASH and fibrosis.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/HEP.0000000000000323

  1. A healthy diet and regular exercise form the foundation of treatment for the vast majority of those with NAFLD.
  2. Patients with NAFLD who are overweight or obese should be prescribed a diet that leads to a caloric deficit. When possible, diets with limited carbohydrates and saturated fat and enriched with high fiber and unsaturated fats (e.g., Mediterranean diet) should be encouraged due to their additional cardiovascular benefits.
  3. Patients with NAFLD should be strongly encouraged to increase their activity level to the extent possible. Individualized prescriptive exercise recommendations may increase sustainability and have benefits independent of weight loss.
  4. Pioglitazone improves NASH and can be considered for patients with NASH in the context of patients with T2DM.
  5. Semaglutide can be considered for its approved indications (T2DM/obesity) in patients with NASH, as it confers a cardiovascular benefit and improves NASH.
  6. Weight loss of 3%–5% improves steatosis, but greater weight loss (>10%) is generally required to improve NASH and fibrosis.
View source ↗